Financial Performance - BBOT reported a net loss of $44.8 million for Q3 2025, compared to a net loss of $17.3 million in Q3 2024, reflecting an increase in operational expenses [11]. - General and administrative (G&A) expenses rose to $14.1 million in Q3 2025 from $1.8 million in Q3 2024, attributed to the initiation of standalone operations and the de-SPAC transaction [10]. Research and Development - Research and development (R&D) expenses for Q3 2025 were $35.1 million, up from $17.9 million in Q3 2024, primarily due to increased clinical trial and manufacturing expenses [10]. - BBOT advanced three ongoing Phase 1 clinical trials, with clinical data readouts expected in 2026 [4]. - BBO-8520 demonstrated a 60% confirmed overall response rate in KRAS G12C NSCLC patients during early Phase 1 dose escalation [5]. - The ongoing Phase 1 BREAKER-101 trial is evaluating BBO-10203 for various cancer types, with initial clinical data expected in the first half of 2026 [8]. Financial Position - As of September 30, 2025, BBOT had cash, cash equivalents, and marketable securities totaling $468.3 million, providing a cash runway expected to last into 2028 [10]. - Total assets amounted to $468.285 billion, reflecting a significant increase compared to the previous year [20]. - Total liabilities reached $380.931 billion, indicating a rise in financial obligations [20]. - Total stockholders' equity was reported at $446.700 billion, showing a growth from the prior year [20]. Corporate Developments - BBOT appointed Uneek Mehra as Chief Financial Officer, bringing over 28 years of experience in the biotechnology and pharmaceutical industries [10]. - BBOT began trading on Nasdaq under the ticker symbol "BBOT" on August 12, 2025, following a business combination with Helix Acquisition Corp. II [10]. - The FDA granted Fast Track designation to BBO-8520 for treating adult patients with previously treated, KRAS G12C-mutated metastatic NSCLC [8].
Helix Acquisition(HLXB) - 2025 Q3 - Quarterly Results